Sirolimus with Neoral Versus Mycophenolate Mofetil with Neoral is Associated with Decreased Renal Allograft Survival
Version of Record online: 26 AUG 2004
American Journal of Transplantation
Volume 4, Issue 12, pages 2058–2066, December 2004
How to Cite
Meier-Kriesche, H.-U., Steffen, B. J., Chu, A. H., Loveland, J. J., Gordon, R. D., Morris, J. A. and Kaplan, B. (2004), Sirolimus with Neoral Versus Mycophenolate Mofetil with Neoral is Associated with Decreased Renal Allograft Survival. American Journal of Transplantation, 4: 2058–2066. doi: 10.1111/j.1600-6143.2004.00624.x
- Issue online: 26 AUG 2004
- Version of Record online: 26 AUG 2004
- Received 21 May 2004, revised and accepted for publication 23 July 2004
- Acute rejection;
- graft survival;
- mycophenolate mofetil;
- renal function;
- renal transplantation;
To evaluate the association between a regimen of cyclosporine microemulsion (CsA) + sirolimus (Rapa) treatment versus CsA and mycophenolate mofetil (MMF) and renal allograft survival, we analyzed 23 016 primary recipients reported to the Scientific Registry of Transplant Recipients between January 1, 1998 and July 26, 2003.
Univariate Kaplan-Meier analysis and multivariate Cox proportional hazard models correcting for demographic and clinical covariates were used to estimate the relative risks for CsA+Rapa versus CsA+MMF-treated patients reaching study endpoints. Subgroup analyses were conducted for recipient ethnicity and donor type.
CsA+Rapa was associated with significantly lower graft survival (74.6% vs. 79.3% at 4 years, p = 0.002) and death-censored graft survival (83.7% vs. 87.2%, p = 0.003) compared to CsA+MMF. In multivariate analyses, CsA+Rapa was associated with a significantly increased risk for graft loss, death-censored graft loss and decline in renal function (HR = 1.22, p = 0.002; HR = 1.22, p = 0.018 and HR = 1.25, p < 0.001, respectively). Similar results were obtained in recipient ethnicity and donor type subgroups.
In summary, CsA+Rapa was associated with significantly worse graft survival and death-censored graft survival compared to CsA+MMF, and likely reflects full-dose CsA +Rapa. Outcomes regarding alternative strategies of Rapa utilization with reduced CsA, with alternative agents or with no calcineurin inhibitor cannot be extrapolated from these data.